14,890 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by NorthCrest Asset Manangement LLC

NorthCrest Asset Manangement LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,890 shares of the biopharmaceutical company's stock, valued at approximately $448,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Arizona State Retirement System lifted its stake in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. lifted its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after buying an additional 463 shares in the last quarter. New York State Teachers Retirement System lifted its stake in TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after buying an additional 837 shares in the last quarter. Finally, Redwood Investments LLC lifted its stake in TG Therapeutics by 0.9% in the fourth quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after buying an additional 886 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Up 1.8%

Shares of NASDAQ TGTX traded up $0.66 during midday trading on Tuesday, reaching $36.41. The company's stock had a trading volume of 1,533,347 shares, compared to its average volume of 2,969,201. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a fifty-two week low of $15.16 and a fifty-two week high of $46.48. The stock has a market capitalization of $5.78 billion, a price-to-earnings ratio of -364.06 and a beta of 2.21. The stock has a 50 day simple moving average of $37.22 and a 200-day simple moving average of $34.51.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter last year, the business earned ($0.07) earnings per share. TG Therapeutics's revenue for the quarter was up 90.4% on a year-over-year basis. Equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on TGTX shares. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.